These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37885403)

  • 1. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
    Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
    Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
    [No Abstract]   [Full Text] [Related]  

  • 2. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
    Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
    Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
    Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
    Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
    Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
    Liu J; Wu Q; Wu S; Xie X
    Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
    Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
    Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
    Kim JY; Lee KH; Kang J; Borcoman E; Saada-Bouzid E; Kronbichler A; Hong SH; de Rezende LFM; Ogino S; Keum N; Song M; Luchini C; van der Vliet HJ; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31683809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
    Chen S; Han L; Guo S; Tan Z; Dai G
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
    Zhao LP; Hu JH; Hu D; Wang HJ; Huang CG; Luo RH; Zhou ZH; Huang XY; Xie T; Lou JS
    Biomed Pharmacother; 2022 Jun; 150():112949. PubMed ID: 35447545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
    Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.